Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
John Koreth(Otsuka (Japan)), Robert J. Soiffer(Dana-Farber Cancer Institute), Dmitrios Tzachanis(Hadassah Medical Center), Jerome Ritz(Dana-Farber Cancer Institute), Ken‐ichi Matsuoka(Okayama University), Sashank Prasad(Brigham and Women's Hospital), Robin Joyce(Beth Israel Deaconess Medical Center), Corey Cutler(Harvard University), Vincent T. Ho(Dana-Farber Cancer Institute), Haesook T. Kim(Dana-Farber Cancer Institute), David Avigan(Beth Israel Deaconess Medical Center), Philippe Armand(Harvard University), Joseph H. Antin(Dana-Farber Cancer Institute), Edwin P. Alyea(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Bhavjot Bindra(Dana-Farber Cancer Institute), Don C. Bienfang, Sean M. McDonough(Harvard University), Nathaniel S. Treister(Brigham and Women's Hospital)
Cited by 1,122
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k